Konishi T, et al. - An inquiry was set up in order to inspect the clinical safety of transurethral resection of bladder tumors (TURBT) in patients receiving anti-thromboembolic agents compared with patients not taking these agents and patients who interrupted their use perioperatively. Experts illustrated that TURBT could be performed safely in patients who continued to take antiplatelet and/or anticoagulant agents. It did not raise the risks of severe hemorrhage and blood transfusion. The risk of postoperative clot retention, nevertheless, could be increased in such patients.